Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
House dust mite (HDM) allergen is a biological extract derived from mites such as *Dermatophagoides pteronyssinus* or *Dermatophagoides farinae*. In clinical research settings, such as those led by the Fraunhofer-Institute of Toxicology and Experimental Medicine, it is utilized as an investigational challenge agent rather than a therapeutic drug. The allergen is typically aerosolized in a controlled Allergen Challenge Chamber (ACC) to induce standardized IgE-mediated allergic responses in sensitized patients. This model is used to study the immunological and clinical skin responses in conditions like atopic dermatitis and allergic rhinitis, facilitating the development of new therapies by providing a reproducible environment for allergen exposure. The specific extract used in the Fraunhofer studies is sourced from ALK-Abello as a lyophilized SQ503 Der p preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on house dust mite allergen.